<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2017.7935</article-id>
<article-id pub-id-type="publisher-id">mmr-17-01-1289</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Protective effects of probucol on Ox-LDL-induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells via LOX-1/ROS/MAPK signaling</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Bing Bing</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref>
<xref rid="fn1-mmr-17-01-1289" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Hao</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref>
<xref rid="fn1-mmr-17-01-1289" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Chi</surname><given-names>Yang Feng</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yun Man</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Yao</surname><given-names>Xing Mei</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shuang</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Huiling</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Fang</surname><given-names>Ji</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Yin</surname><given-names>Pei Hao</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xue Mei</given-names></name>
<xref rid="af2-mmr-17-01-1289" ref-type="aff">2</xref>
<xref rid="c2-mmr-17-01-1289" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Peng</surname><given-names>Wen</given-names></name>
<xref rid="af1-mmr-17-01-1289" ref-type="aff">1</xref>
<xref rid="c1-mmr-17-01-1289" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-mmr-17-01-1289"><label>1</label>Department of Nephrology, Laboratory of Renal Disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China</aff>
<aff id="af2-mmr-17-01-1289"><label>2</label>Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-17-01-1289"><italic>Correspondence to</italic>: Professor Wen Peng, Department of Nephrology, Laboratory of Renal Disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, 164 Lanxi Road, Shanghai 200062, P.R. China, E-mail: <email>pengwen_01@vip.sina.com</email></corresp>
<corresp id="c2-mmr-17-01-1289">Professor Xue Mei Zhang, Department of Pharmacology, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, P.R. China, E-mail: <email>xuemzhang@fudan.edu.cn</email></corresp>
<fn id="fn1-mmr-17-01-1289"><label>&#x002A;</label><p>Contributed equally</p></fn>
</author-notes>
<pub-date pub-type="ppub"><month>01</month><year>2018</year></pub-date>
<pub-date pub-type="epub"><day>02</day><month>11</month><year>2017</year></pub-date>
<volume>17</volume>
<issue>1</issue>
<fpage>1289</fpage>
<lpage>1296</lpage>
<history>
<date date-type="received"><day>07</day><month>11</month><year>2016</year></date>
<date date-type="accepted"><day>19</day><month>09</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2018, Spandidos Publications</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<abstract>
<p>Oxidized low-density lipoprotein (Ox-LDL), as a strong oxidant, results in renal injury through multiple mechanisms. The aim of the present study was to determine the injury effects of Ox-LDL and the potential protective effects of the antioxidant reagent probucol on epithelial-mesenchymal transition (EMT) in human renal proximal tubular epithelial cells (HK-2) and to further explore the role and interrelation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), reactive oxygen species (ROS) and mitogen-activated protein kinase (MAPK) pathway. In the present study, concentrations of 0&#x2013;100 &#x00B5;g/ml Ox-LDL were used to induce HK-2 cell EMT. Then, probucol (20 &#x00B5;mol/l) and the LOX-1 inhibitor, polyinosinic acid (250 &#x00B5;g/ml), were also used to pretreat HK-2 cells. Intracellular ROS activity was evaluated using the specific probe 2&#x2032;,7&#x2032;-dichlorodihydrofluorescein diacetate (DCFH-DA). Concentration of nitric oxide (NO) was determined using a biochemical colorimetric method. Expression of E-cadherin, &#x03B1;-smooth muscle actin (SMA), LOX-1, NADPH oxidase 4 (NOX4), cytochrome b-245 &#x03B1; chain (p22phox), extracellular signal-regulated kinase (ERK), and p38 MAPK protein levels were examined by western blotting. The results revealed that Ox-LDL induced the expression of LOX-1 and &#x03B1;-SMA and reduced the expression of E-cadherin in a dose-dependent manner, and these effects were inhibited by polyinosinic acid or probucol pretreatment. Stimulation with 50 &#x00B5;g/ml Ox-LDL induced the expression of NOX4 and p22phox and increased intracellular ROS activity, but NO production in the cell supernatants was not affected. The Ox-LDL-mediated increases in Nox4 and p22phox expression and in ROS activity were inhibited by probucol pretreatment. Further investigations into the underlying molecular pathways demonstrated that ERK and p38 MAPK were activated by Ox-LDL stimulation and then inhibited by probucol pretreatment. The findings of the present study therefore suggest that Ox-LDL induced EMT in HK-2 cells, the mechanism of which may be associated with LOX-1-related oxidative stress via the ERK and p38 MAPK pathways. Notably, pretreatment with probucol inhibited the Ox-LDL-induced oxidative stress by reducing the expression of LOX-1, and blocked the progression of EMT.</p>
</abstract>
<kwd-group>
<kwd>epithelial-mesenchymal transition</kwd>
<kwd>oxidized low-density lipoprotein</kwd>
<kwd>probucol</kwd>
<kwd>lectin-like oxidized low-density lipoprotein receptor-1</kwd>
<kwd>mitogen-activated protein kinase pathway</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Epithelial-mesenchymal transition (EMT) of renal proximal tubular epithelial cells in adult kidneys is one of the key events that occurs during the development of renal tubulointerstitial fibrosis (<xref rid="b1-mmr-17-01-1289" ref-type="bibr">1</xref>&#x2013;<xref rid="b5-mmr-17-01-1289" ref-type="bibr">5</xref>), contributing to renal fibrogenesis. Previous research has demonstrated that various injury factors (including high blood glucose, proteinuria, hypertension, high blood cholesterol, high protein intake and uremic toxins) can all lead to renal tubular injury, which then aggravates the progression of renal fibrosis (<xref rid="b6-mmr-17-01-1289" ref-type="bibr">6</xref>&#x2013;<xref rid="b9-mmr-17-01-1289" ref-type="bibr">9</xref>). Recently, dysregulation of lipid metabolism in the occurrence and development of renal interstitial fibrosis, has received increasingly widespread awareness by international kidney disease experts. Oxidized low-density lipoprotein (Ox-LDL), the most widely studied of all lipoproteins, has been reported to cause renal injuries through multiple mechanisms. Ox-LDL, a LDL oxidation product with potent cell cytotoxic properties, is considered an indicator of oxidative stress levels in mesangial cells, which can trigger intracellular lipid oxidation, release of reactive nitrogen and reactive oxygen species (ROS), and deteriorative oxidative stress, thus further promoting cell injury (<xref rid="b10-mmr-17-01-1289" ref-type="bibr">10</xref>). However, previous studies have focused on renal intraglomerular mesangial cells, endothelial cells and monocyte/macrophage cells, and explored the roles of Ox-LDL in promoting glomerular injuries and sclerosis (<xref rid="b10-mmr-17-01-1289" ref-type="bibr">10</xref>&#x2013;<xref rid="b12-mmr-17-01-1289" ref-type="bibr">12</xref>). Few research results have been reported on the injury effects and mechanisms of Ox-LDL in human renal proximal tubular epithelial cells and on whether antioxidant therapy could alleviate the injury.</p>
<p>Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a receptor of Ox-LDL that was first discovered and identified in bovine aortic endothelial cells (<xref rid="b13-mmr-17-01-1289" ref-type="bibr">13</xref>), is expressed in endothelial cells, macrophages, vascular smooth muscle cells, platelets, and adipocytes, but also in epithelial cells (<xref rid="b14-mmr-17-01-1289" ref-type="bibr">14</xref>,<xref rid="b15-mmr-17-01-1289" ref-type="bibr">15</xref>). As LOX-1 can bind to multiple ligands, it has diverse physiological functions and critical roles in signal transduction.</p>
<p>Oxidative stress, a major cause of cell damage, aging and cell death, has recently received increasing attention regarding its role in renal tubule injury. Kidney tissues require a higher oxygen consumption to complete the active transport and reabsorption of water and electrolytes. Therefore, renal tubules are more susceptible to oxidative damage. As a second messenger in a variety of signaling pathways, ROS participates in numerous physiological and pathological processes, including proliferation, differentiation and apoptosis (<xref rid="b16-mmr-17-01-1289" ref-type="bibr">16</xref>&#x2013;<xref rid="b19-mmr-17-01-1289" ref-type="bibr">19</xref>). It is generally accepted that damage of ROS to the kidney is normally in the deposition of glomerular extracellular matrix (ECM) and renal tubular EMT (<xref rid="b20-mmr-17-01-1289" ref-type="bibr">20</xref>&#x2013;<xref rid="b22-mmr-17-01-1289" ref-type="bibr">22</xref>). Probucol, as an antioxidant and anti-inflammatory drug, reduces ROS production. It has been reported that probucol could ameliorate renal tubular EMT in a diabetic nephropathy rat model (<xref rid="b23-mmr-17-01-1289" ref-type="bibr">23</xref>).</p>
<p>Previous studies have suggested that the dysregulation of lipid metabolism may also be involved in the renal tubular transdifferentiation process, and ultimately may lead to the occurrence of renal interstitial fibrosis (<xref rid="b24-mmr-17-01-1289" ref-type="bibr">24</xref>). However, there is little evidence supporting this hypothesis and the mechanism remains unclear. For that purpose, the present study examined the EMT status and the LOX-1 and ROS production in cultured renal proximal tubular cells induced with Ox-LDL. In addition, the molecular mechanism and downstream signaling pathways of LOX-1 and ROS were investigated, as well as the potential protective effects of the antioxidant reagent probucol on the above processes.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture</title>
<p>Human HK-2 renal proximal tubule epithelial cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco&#x0027;s modified Eagles medium (DMEM)-F12 medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10&#x0025; fetal bovine serum (Biochrom, Ltd., Cambridge, UK), L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 &#x00B5;g/ml) (all from Thermo Fisher Scientific, Inc.) in a humidified incubator containing 5&#x0025; CO<sub>2</sub> at 37&#x00B0;C. Cells were pretreated with 20 &#x00B5;mol/l probucol or 250 &#x00B5;g/ml LOX-1 inhibitor polyinosinic acid (both from Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 2 h in advance, and stimulated with Ox-LDL (0&#x2013;100 &#x00B5;g/ml; Peking Union-Biology Co., Ltd., Beijing, China) for 24 h.</p>
</sec>
<sec>
<title>MTT assay</title>
<p>Cells plated in 96-well plates (2&#x00D7;10<sup>4</sup>/well) in 200 &#x00B5;l medium were treated with 50 &#x00B5;g/ml Ox-LDL for 0&#x2013;72 h or 0&#x2013;200 &#x00B5;g/ml Ox-LDL for 24 h. Cells were incubated with 20 &#x00B5;l 5 g/l MTT solution (Sigma-Aldrich; Merck KGaA) for 4 h. The supernatant was then removed, and 100 &#x00B5;l of DMSO was added to each well. The absorbance at 570 nm was measured using a spectrophotometric plate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Results were quantified from four independent experiments.</p>
</sec>
<sec>
<title>Nitric oxide (NO) measurement</title>
<p>NO was determined using the Total NO assay kit (Beyotime Institute of Biotechnology, Shanghai, China). HK-2 cells were seeded in 96-well culture plates (8&#x00D7;10<sup>4</sup> cells/well), pretreated with 20 &#x00B5;mol/l probucol or 250 &#x00B5;g/ml LOX-1 inhibitor polyinosinic acid as mentioned above, and then stimulated with 50 &#x00B5;g/m1 Ox-LDL for 24 h at 37&#x00B0;C. Then, the culture supernatants were used to determine the concentration of NO. The standard provided in the kit was diluted with DMEM-F12 medium to a variety of concentrations, as indicated: 0, 1, 2, 5, 10, 20, 40, 60 and 100 &#x00B5;g/ml. Afterwards, the supernatant of each sample or 50 &#x00B5;l of the above standard were added in a 96-well plate together with 50 &#x00B5;l Griess Reagent I and Griess Reagent II. The absorbance at 550 nm was measured using a spectrophotometric plate reader (Bio-Rad Laboratories, Inc.). Results were quantified from four independent experiments.</p>
</sec>
<sec>
<title>Intracellular ROS measurement</title>
<p>The intracellular ROS levels were measured using the specific probe 2&#x2032;,7&#x2032;-dichlorodihydrofluorescein diacetate (DCFH-DA; Beyotime Institute of Biotechnology) kit. HK-2 cells seeded (8&#x00D7;10<sup>5</sup> cells/well) in 6-well cell culture plates were pretreated by probucol or polyinosinic acid as mentioned above, and then stimulated with 50 &#x00B5;g/m1 Ox-LDL for 24 h at 37&#x00B0;C. Afterwards, serum-free medium containing 10 &#x00B5;M DCFH-DA was added to each well for 20 min at 37&#x00B0;C in the dark. In order to fully remove the remaining DCFH-DA, the cells were washed with serum-free medium three times, then detached from the plates with 0.25&#x0025; trypsin, and collected by centrifugation at 300 &#x00D7; g for 5 min at 4&#x00B0;C. Positive control cells were simultaneously treated with Rosup (a ROS positive control provided by the kit). FACScan flow cytometric and CellQuest Pro software v5.1 (both from BD Biosciences, San Jose, CA, USA) analyses were conducted on the various cell treatment groups to detect the average fluorescence intensity of dichlorofluorescein (DCF), at an excitation wavelength of 488 nm and at an emission wavelength of 525 nm. Results were quantified from four independent experiments.</p>
</sec>
<sec>
<title>Western blotting</title>
<p>Proteins were extracted using a radioimmunoprecipitation lysis buffer (Beyotime Institute of Biotechnology) that contains the protease inhibitor cocktail (Sigma-Aldrich; Merck KGaA) and protein concentrations were calculated by using the Pierce bicinchoninic protein assay kit (Thermo Fisher Scientific, Inc.). An equal amount of protein (40 &#x00B5;g) was taken from each group. The samples were mixed with 5X SDS sample buffer and heated at 100&#x00B0;C for 5 min, then loaded onto 10 or 12&#x0025; Tris-glycine SDS-PAGE gel and separated at 100 V for 1.5 to 2 h. Primary antibodies against E-cadherin (cat no. 14472; 1:1,000), extracellular signal-regulated kinase (ERK; cat no. 4696; 1:2,000), phosphorylated (p-) ERK (cat no. 4094; 1:1,000), p38 (cat no. 9218; 1:1,000) and p-p38 (cat no. 9216; 1:2,000) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Primary antibodies against LOX-1 (cat no. sc-20753; 1:300), NADPH oxidase 4 (NOX4; cat no. sc-30141; 1:300), and p22phox (cat no. sc-271968; 1:200) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Primary antibodies against &#x03B1;-SMA (cat no. A2547; 1:500) and &#x03B2;-actin (cat no. A5441; 1:1,000) were purchased from Sigma-Aldrich (Merck KGaA). Following transferring of proteins to a polyvinylidene fluoride membrane, nonspecific binding to the membrane was blocked with 5&#x0025; non-fat dry milk for 2 h at room temperature. The membranes were then incubated overnight at 4&#x00B0;C with primary antibodies against LOX-1, &#x03B1;-SMA, E-cadherin, NOX4, p22phox, ERK, p-ERK, ERK, p-p38, and p38. Following washing, membranes were incubated with goat anti-mouse (cat no. BA1051; 1:2,000) or anti-rabbit (cat no. BA1055; 1:2,000) (both from Wuhan Boster Biological Technology, Ltd., Wuhan, China) horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. The signals were visualized by enhanced chemiluminescence (Pierce; Thermo Fisher Scientific, Inc.). ImageJ 1.37 (National Institute of health, Bethesda, MD, USA) analysis system was used to analyze the signal absorbance.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Statistical analyses were performed using SPSS software (version 21.0; IBM SPSS, Armonk, NY, USA). All the data represent at least three independent experiments and are expressed as the means &#x00B1; standard deviation unless otherwise indicated. Differences between groups were determined using an unpaired Student&#x0027;s t-test or a one-way analysis of variance (anova; S-N-K post hoc test was used after the anova) when multiple comparisons were required. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Effect of Ox-LDL on the viability of HK-2 cells</title>
<p>The effect of Ox-LDL stimulation on the viability of HK-2 cells was examined using the MTT assay. The results demonstrated that there was a slight decrease in the total numbers of viable cells in the Ox-LDL-stimulated groups in different times (24&#x2013;72 h) but over the range of different dosages (12.5&#x2013;200 &#x00B5;g/ml) after 24 h there was only a small change in cell viability, compared with the control untreated group (<xref rid="f1-mmr-17-01-1289" ref-type="fig">Fig. 1</xref>). However, the differences were not significant (P&#x003E;0.05), suggesting that Ox-LDL had no effect on the viability of HK-2 cells at the doses and times tested.</p>
</sec>
<sec>
<title>Effect of Ox-LDL on &#x03B1;-SMA, E-cadherin and LOX-1 protein expression in HK-2 cells</title>
<p>To investigate the effects of Ox-LDL stimulation on EMT in HK-2cells, the protein expression levels of the mesenchymal marker &#x03B1;-SMA and of the epithelial marker E-cadherin, as well as LOX-1 expression, were determined by western blotting. The results demonstrated that stimulation with Ox-LDL (25&#x2013;100 &#x00B5;g/ml) resulted in a significant increase in the expression of LOX-1 and &#x03B1;-SMA in HK-2 cells in a dose-dependent manner, while E-cadherin expression was significantly decreased (<xref rid="f2-mmr-17-01-1289" ref-type="fig">Fig. 2</xref>).</p>
</sec>
<sec>
<title>Effect of probucol on &#x03B1;-SMA, E-cadherin, and LOX-1 protein expression in Ox-LDL-stimulated HK-2 cells</title>
<p>According to the above results, the dose of 50 &#x00B5;g/ml Ox-LDL was selected to stimulate HK-2 cells in the following experiments. Cells were pretreated with probucol (20 &#x00B5;mol/l) or the LOX-1 inhibitor polyinosinic acid (250 &#x00B5;g/ml), stimulated with Ox-LDL and then analyzed by western blotting. The results demonstrated a significant increase in &#x03B1;-SMA and LOX-1 protein expression levels in HK-2 cells stimulated with 50 &#x00B5;g/ml Ox-LDL, and this effect was significantly inhibited by probucol or polyinosinic acid pretreatment (<xref rid="f3-mmr-17-01-1289" ref-type="fig">Fig. 3</xref>). Of note, the inhibition of LOX-1 expression by probucol was weaker than by polyinosinic acid (<xref rid="f3-mmr-17-01-1289" ref-type="fig">Fig. 3</xref>). E-cadherin protein expression levels exhibited the opposite effect, with decreasing levels following Ox-LDL stimulation and increasing levels following probucol or polyinosinic acid pretreatment (<xref rid="f3-mmr-17-01-1289" ref-type="fig">Fig. 3</xref>).</p>
</sec>
<sec>
<title>Effects of probucol on ROS and NO production in Ox-LDL-stimulated HK-2 cells</title>
<p>To specify whether oxidative stress was involved in the process of EMT in HK-2 cells induced by Ox-LDL, the production of ROS was examined using the specific probe DCFH-DA and the concentration of NO was detected using a biochemical colorimetric method. The results revealed that the basic activity of ROS in HK-2 cells was 451.5 &#x00B5;g/ml. Following stimulation with 50 &#x00B5;g/ml Ox-LDL, ROS activity increased to 839.8 &#x00B5;g/ml (P&#x003C;0.05; <xref rid="f4-mmr-17-01-1289" ref-type="fig">Fig. 4A</xref>), however, this increase was inhibited by probucol or polyinosinic acid pretreatment (P&#x003C;0.05; <xref rid="f4-mmr-17-01-1289" ref-type="fig">Fig. 4A</xref>). The concentration of NO in the culture supernatant of the control unstimulated HK-2 cells was 46.0 &#x00B5;mol/l (<xref rid="f4-mmr-17-01-1289" ref-type="fig">Fig. 4B</xref>). Following stimulation with 50 &#x00B5;g/ml Ox-LDL, NO concentration was 46.2 &#x00B5;mol/l, which was not significantly different compared with control (P&#x003E;0.05; <xref rid="f4-mmr-17-01-1289" ref-type="fig">Fig. 4B</xref>). Similarly, pretreatment with probucol or polyinosinic acid did not have any effect on NO concentration (P&#x003E;0.05; <xref rid="f4-mmr-17-01-1289" ref-type="fig">Fig. 4B</xref>).</p>
</sec>
<sec>
<title>Effects of probucol on NOX4 and p22phox expression in Ox-LDL-stimulated HK-2 cells</title>
<p>Because NADPH oxidase activation is a major source of ROS in cells, the effect of probucol on the oxidative stress-related proteins NOX4 and p22phox was examined in HK-2 cells induced by Ox-LDL. Western blot analysis demonstrated an obvious increase in the protein expression levels of NOX4 and p22phox following OX- LDL stimulation (<xref rid="f4-mmr-17-01-1289" ref-type="fig">Fig. 4C</xref>). However, pretreatment with probucol or polyinosinic acid significantly suppressed these increases (P&#x003C;0.05; <xref rid="f4-mmr-17-01-1289" ref-type="fig">Fig. 4C</xref>).</p>
</sec>
<sec>
<title>Effect of probucol on ERK1/2 and p38 MAPK signaling pathways in Ox-LDL-induced HK-2 cells</title>
<p>To further understand the mechanism responsible for the Ox-LDL-induced EMT in renal tubular epithelial cells, the activation status of the ERK1/2 and p38 MAPK signaling pathways was investigated. Following Ox-LDL stimulation in HK-2 cells, an increase in both ERK1/2 and p38 phosphorylation was observed at 5 min of stimulation, and peaking at 30 min (<xref rid="f5-mmr-17-01-1289" ref-type="fig">Fig. 5A</xref>). ERK1/2 and p38 phosphorylation was significantly inhibited by pretreatment with probucol or polyinosinic acid (<xref rid="f5-mmr-17-01-1289" ref-type="fig">Fig. 5B</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Renal fibrosis, characterized by glomerulosclerosis and tubulointerstitial fibrosis, is the final common pathway of a wide variety of chronic kidney disease (CKD) leading to the complete destruction of kidney parenchyma and end-stage renal disease, requiring dialysis or kidney transplant (<xref rid="b25-mmr-17-01-1289" ref-type="bibr">25</xref>). Studies have demonstrated that in renal fibrosis, the correlation of renal tubulointerstitial fibrosis with renal function is much closer than of glomerulosclerosis (<xref rid="b26-mmr-17-01-1289" ref-type="bibr">26</xref>). The renal proximal tubular epithelial cells, which are susceptible to injuries by a wide variety of factors, are generally considered to have a pivotal role in fibrogenesis. The proximal tubular epithelial cells undergo EMT, resulting in matrix-producing fibroblasts, and thereby contributing to the pathogenesis of renal interstitial fibrosis and end-stage renal failure.</p>
<p>In the present study, the lipoprotein Ox-LDL was demonstrated to induce EMT in tubular epithelial cells. A small amount of LOX-1 expression was observed in control HK-2 cells, which was then upregulated by Ox-LDL stimulation in a dose-dependent manner, indicating that LOX-1 may have contributed to the EMT of proximal tubular epithelial cells. In order to determine the mechanism of LOX-1 in the injury of HK-2 cells, the LOX-1 inhibitor polyinosinic acid and the antioxidant probucol were used to pretreat the cells. The results indicated that pretreatment suppressed both LOX-1 expression and EMT. In addition, Ox-LDL was demonstrated to induce oxidative stress, with expression of p22phox and NOX4 and production of ROS significantly increased in HK-2 cells following Ox-LDL stimulation. However, these increases were inhibited by pretreatment with the LOX-1 inhibitor or probucol. No significant differences were observed in NO concentration in any of the treatment groups. Of note, the inhibition of LOX-1 by probucol was weaker than by the LOX-1 inhibitor, suggesting that Ox-LDL induced LOX-1 expression, which may have activated NADPH oxidase-mediated ROS generation and LOX-1 upregulation. These observations provide evidence for a positive feedback loop involving Ox-LDL, NADPH oxidase-mediated ROS generation and LOX-1.</p>
<p>Recently, there has been increasing interest in the role of LOX-1 in the progression of renal diseases. A previous study has reported that high glucose levels can induce the expression of LOX-1 at the gene promoter/transcription level via a p38 MAPK-dependent mechanism, leading to Ox-LDL-induced apoptosis in renal tubular epithelial cells (<xref rid="b27-mmr-17-01-1289" ref-type="bibr">27</xref>). It has also been reported that LOX-1 and NADPH oxidase are upregulated in human renal proximal tubular epithelial cells induced with angiotensin II (Ang II), and that the activation of the MAPK pathway occurs downstream of the Ang II/ROS/LOX-1 cascade (<xref rid="b28-mmr-17-01-1289" ref-type="bibr">28</xref>). A study in LDLr-null mice has demonstrated that high fat diet induced renal fibrosis through activation of the LOX-1/p38, p44/42/nuclear factor-&#x03BA;B pathway by Ox-LDL (<xref rid="b29-mmr-17-01-1289" ref-type="bibr">29</xref>). The above studies suggest that an increase in LOX-1 expression is observed in renal tubular epithelial cells, and this is associated with the pathogenesis and progression of chronic renal tubular and interstitial diseases. The present results demonstrated that LOX-1 expression was increased following Ox-LDL stimulation and EMT induction in HK-2 cells, which is consistent with previous studies.</p>
<p>Renal tubules are known to be susceptible to injury from oxidative stress, in which ROS are crucial cell-damaging molecules. Studies reveal that ROS induces apoptosis and EMT in renal tubular epithelial cells through the MAPK pathway (<xref rid="b20-mmr-17-01-1289" ref-type="bibr">20</xref>,<xref rid="b30-mmr-17-01-1289" ref-type="bibr">30</xref>,<xref rid="b31-mmr-17-01-1289" ref-type="bibr">31</xref>). High glucose induces EMT by decreasing intracellular ROS levels via the downregulation of NADPH oxidase subunits NOX1 and NOX4, and activation of ERK1/2 is associated with high glucose-induced EMT in HK-2 cells (<xref rid="b21-mmr-17-01-1289" ref-type="bibr">21</xref>). The present results demonstrated that Ox-LDL stimulation triggered oxidative stress and NOX4 and p22phox upregulation, but NO was not involved in this process.</p>
<p>The MAPK pathway, which includes ERK, c-Jun N-terminal kinase (JNK) and p38 MAPKs (<xref rid="b32-mmr-17-01-1289" ref-type="bibr">32</xref>&#x2013;<xref rid="b34-mmr-17-01-1289" ref-type="bibr">34</xref>), can be activated by ROS. Previous studies have demonstrated that ERK and p38 MAPK signaling pathways have a vital role in EMT, inflammation of renal proximal tubule epithelial cells and renal injury (<xref rid="b33-mmr-17-01-1289" ref-type="bibr">33</xref>,<xref rid="b35-mmr-17-01-1289" ref-type="bibr">35</xref>&#x2013;<xref rid="b39-mmr-17-01-1289" ref-type="bibr">39</xref>). Zhou <italic>et al</italic> (<xref rid="b38-mmr-17-01-1289" ref-type="bibr">38</xref>) reported that the knockdown of thioredoxin-interacting protein antagonized the high glucose-induced EMT by inhibiting ROS production and by activation of p38 MAPK and ERK1/2 (<xref rid="b40-mmr-17-01-1289" ref-type="bibr">40</xref>). ROS is also important in transforming growth factor-&#x03B2;1-induced EMT, primarily through activation of p38, ERK MAPKs, and the subsequent ERK-directed activation of the Smad pathway in proximal tubular epithelial cells (<xref rid="b20-mmr-17-01-1289" ref-type="bibr">20</xref>). Consistent with previous studies, probucol and polyinosinic acid pretreatments were demonstrated to prevent the Ox-LDL-mediated activation of ERK and p38 MAPKs in HK-2 cells, indicating that probucol may protect HK-2 cells against Ox-LDL-induced EMT by modulating the ERK and p38 MAPK signaling pathways.</p>
<p>Probucol is a phenolic lipid-lowering prototype agent with anti-inflammatory and antioxidant properties, and has a long history of clinical application for the treatment and prevention of cardiovascular diseases. Its ability to consume oxidation substances, such as oxygen free radicals, serves an important role in its antioxidant, anti-inflammatory and antiapoptotic functions. In a rat model of diabetic nephropathy, probucol inhibited EMT in renal tubular epithelial cells by downregulating specificity protein 1 expression in kidney (<xref rid="b23-mmr-17-01-1289" ref-type="bibr">23</xref>). It has also been reported to attenuate podocytes injury in type 2 diabetic nephropathy of db/db mice through the suppression of NADPH oxidase NOX2 (<xref rid="b41-mmr-17-01-1289" ref-type="bibr">41</xref>). The present data revealed that probucol may have a protective role on the injury of HK-2 cells by modulating LOX-1 and oxidative stress.</p>
<p>There is controversy regarding the use of probucol in cardiovascular diseases and some western countries have stopped its use because of the reduction in serum HDL-cholesterol (HDL-C). However the HDL-C reduction may not be a &#x2018;side effect&#x2019; but may reflect a mechanism of action of probucol as it causes a decrease in HDL-C by enhancing plasma cholesteryl ester transfer protein activity and hepatic scavenger receptor class B type I. Probucol also accelerates the antioxidant function of HDL via increasing paraoxonase 1 activity (<xref rid="b42-mmr-17-01-1289" ref-type="bibr">42</xref>). In particular, a significant coronary artery disease risk reduction has been demonstrated in the long-term treatment of patients with heterozygous familial hypercholesterolemia (FH) in Japan with probucol (<xref rid="b43-mmr-17-01-1289" ref-type="bibr">43</xref>). And there is also evidence for the pleiotropic and beneficial therapeutic effects of probucol on the cardiovascular system and in chronic kidney disease (<xref rid="b42-mmr-17-01-1289" ref-type="bibr">42</xref>,<xref rid="b44-mmr-17-01-1289" ref-type="bibr">44</xref>). As a result of these studies it is clear that probucol may have beneficial therapeutic effects in certain suitable CKD patients. In conclusion, probucol may postpone renal interstitial fibrosis through the suppression of Ox-LDL-induced EMT in HK-2 cells via the downregulation of LOX-1, NADPH oxidase, and ROS production and the inhibition of MAPK signaling activation. The present findings suggest that probucol may serve as a useful antioxidant agent for postponing the progression of renal interstitial diseases. However, further <italic>in vivo</italic> and <italic>in vitro</italic> studies are needed to elucidate the mechanism involved.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by funding from the National Natural Science Foundation of China (grant no. 81473480), Key Medical Discipline Project Shanghai Municipal Health Bureau (grant no. ZK2015A18), Independent Innovation Research Fund of Putuo District Science and Technology Committee (grant no. 2012PTKW006), Potential Health Professionals in Shanghai University of Traditional Chinese Medicine (grant no. B-X-78), and Shanghai Municipal Health and Family Planning Commission (grant no. 201540056).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-mmr-17-01-1289"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galichon</surname><given-names>P</given-names></name><name><surname>Hertig</surname><given-names>A</given-names></name></person-group><article-title>Epithelial to mesenchymal transition as a biomarker in renal fibrosis: Are we ready for the bedside?</article-title><source>Fibrogenesis Tissue Repair</source><volume>4</volume><fpage>11</fpage><year>2011</year><pub-id pub-id-type="doi">10.1186/1755-1536-4-11</pub-id><pub-id pub-id-type="pmid">21470408</pub-id><pub-id pub-id-type="pmcid">3079627</pub-id></element-citation></ref>
<ref id="b2-mmr-17-01-1289"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Kanasaki</surname><given-names>K</given-names></name></person-group><article-title>Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease</article-title><source>Clin Exp Nephrol</source><volume>17</volume><fpage>488</fpage><lpage>497</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s10157-013-0781-0</pub-id><pub-id pub-id-type="pmid">23430391</pub-id></element-citation></ref>
<ref id="b3-mmr-17-01-1289"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carew</surname><given-names>RM</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Kantharidis</surname><given-names>P</given-names></name></person-group><article-title>The role of EMT in renal fibrosis</article-title><source>Cell Tissue Res</source><volume>347</volume><fpage>103</fpage><lpage>116</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s00441-011-1227-1</pub-id><pub-id pub-id-type="pmid">21845400</pub-id></element-citation></ref>
<ref id="b4-mmr-17-01-1289"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Renal fibrosis: New insights into the pathogenesis and therapeutics</article-title><source>Kidney Int</source><volume>69</volume><fpage>213</fpage><lpage>217</lpage><year>2006</year><pub-id pub-id-type="doi">10.1038/sj.ki.5000054</pub-id><pub-id pub-id-type="pmid">16408108</pub-id></element-citation></ref>
<ref id="b5-mmr-17-01-1289"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>SJ</given-names></name></person-group><article-title>Fibrosis: Targeting EMT to reverse renal fibrosis</article-title><source>Nat Rev Nephrol</source><volume>11</volume><fpage>565</fpage><year>2015</year><pub-id pub-id-type="doi">10.1038/nrneph.2015.133</pub-id><pub-id pub-id-type="pmid">26241016</pub-id></element-citation></ref>
<ref id="b6-mmr-17-01-1289"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zha</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>YH</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>High glucose instigates tubulointerstitial injury by stimulating hetero-dimerization of adiponectin and angiotensin II receptors</article-title><source>Biochem Biophys Res Commun: pii: S0006-291X(17)31600-5</source><year>2017</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.08.047</pub-id></element-citation></ref>
<ref id="b7-mmr-17-01-1289"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahl</surname><given-names>P</given-names></name><name><surname>Ducasa</surname><given-names>GM</given-names></name><name><surname>Fornoni</surname><given-names>A</given-names></name></person-group><article-title>Systemic and renal lipids in kidney disease development and progression</article-title><source>Am J Physiol Renal Physiol</source><volume>310</volume><fpage>F433</fpage><lpage>F445</lpage><year>2016</year><pub-id pub-id-type="doi">10.1152/ajprenal.00375.2015</pub-id><pub-id pub-id-type="pmid">26697982</pub-id></element-citation></ref>
<ref id="b8-mmr-17-01-1289"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuenca-S&#x00E1;nchez</surname><given-names>M</given-names></name><name><surname>Navas-Carrillo</surname><given-names>D</given-names></name><name><surname>Orenes-Pi&#x00F1;ero</surname><given-names>E</given-names></name></person-group><article-title>Controversies surrounding high-protein diet intake: Satiating effect and kidney and bone health</article-title><source>Adv Nutr</source><volume>6</volume><fpage>260</fpage><lpage>266</lpage><year>2015</year><pub-id pub-id-type="doi">10.3945/an.114.007716</pub-id><pub-id pub-id-type="pmid">25979491</pub-id><pub-id pub-id-type="pmcid">4424780</pub-id></element-citation></ref>
<ref id="b9-mmr-17-01-1289"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noone</surname><given-names>D</given-names></name><name><surname>Licht</surname><given-names>C</given-names></name></person-group><article-title>Chronic kidney disease: A new look at pathogenetic mechanisms and treatment options</article-title><source>Pediatr Nephrol</source><volume>29</volume><fpage>779</fpage><lpage>792</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s00467-013-2436-5</pub-id><pub-id pub-id-type="pmid">23471475</pub-id></element-citation></ref>
<ref id="b10-mmr-17-01-1289"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Song</surname><given-names>CY</given-names></name></person-group><article-title>Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis</article-title><source>Am J Nephrol</source><volume>29</volume><fpage>62</fpage><lpage>70</lpage><year>2009</year><pub-id pub-id-type="doi">10.1159/000151277</pub-id><pub-id pub-id-type="pmid">18689980</pub-id></element-citation></ref>
<ref id="b11-mmr-17-01-1289"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>BC</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Choi</surname><given-names>KH</given-names></name><name><surname>Chung</surname><given-names>HK</given-names></name></person-group><article-title>Involvement of oxidation in LDL-induced collagen gene regulation in mesangial cells</article-title><source>Kidney Int</source><volume>50</volume><fpage>1582</fpage><lpage>1590</lpage><year>1996</year><pub-id pub-id-type="doi">10.1038/ki.1996.474</pub-id><pub-id pub-id-type="pmid">8914025</pub-id></element-citation></ref>
<ref id="b12-mmr-17-01-1289"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurukulasuriya</surname><given-names>Romayne L</given-names></name><name><surname>Athappan</surname><given-names>G</given-names></name><name><surname>Saab</surname><given-names>G</given-names></name><name><surname>Connell</surname><given-names>Whaley A</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name></person-group><article-title>HMG CoA reductase inhibitors and renoprotection: The weight of the evidence</article-title><source>Ther Adv Cardiovasc Dis</source><volume>1</volume><fpage>49</fpage><lpage>59</lpage><year>2007</year><pub-id pub-id-type="doi">10.1177/1753944707082714</pub-id><pub-id pub-id-type="pmid">19124395</pub-id></element-citation></ref>
<ref id="b13-mmr-17-01-1289"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawamura</surname><given-names>T</given-names></name><name><surname>Kume</surname><given-names>N</given-names></name><name><surname>Aoyama</surname><given-names>T</given-names></name><name><surname>Moriwaki</surname><given-names>H</given-names></name><name><surname>Hoshikawa</surname><given-names>H</given-names></name><name><surname>Aiba</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Miwa</surname><given-names>S</given-names></name><name><surname>Katsura</surname><given-names>Y</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Masaki</surname><given-names>T</given-names></name></person-group><article-title>An endothelial receptor for oxidized low-density lipoprotein</article-title><source>Nature</source><volume>386</volume><fpage>73</fpage><lpage>77</lpage><year>1997</year><pub-id pub-id-type="doi">10.1038/386073a0</pub-id><pub-id pub-id-type="pmid">9052782</pub-id></element-citation></ref>
<ref id="b14-mmr-17-01-1289"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>BY</given-names></name><name><surname>Megyesi</surname><given-names>J</given-names></name><name><surname>Kaushal</surname><given-names>GP</given-names></name><name><surname>Safirstein</surname><given-names>RL</given-names></name><name><surname>Mehta</surname><given-names>JL</given-names></name></person-group><article-title>Deletion of LOX-1 attenuates renal injury following angiotensin II infusion</article-title><source>Kidney Int</source><volume>76</volume><fpage>521</fpage><lpage>527</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/ki.2009.234</pub-id><pub-id pub-id-type="pmid">19553911</pub-id></element-citation></ref>
<ref id="b15-mmr-17-01-1289"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>KJ</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Patterson</surname><given-names>CE</given-names></name><name><surname>Temm</surname><given-names>C</given-names></name><name><surname>Dominguez</surname><given-names>JH</given-names></name></person-group><article-title>LOX-1 and inflammation: A new mechanism for renal injury in obesity and diabetes</article-title><source>Am J Physiol Renal Physiol</source><volume>294</volume><fpage>F1136</fpage><lpage>F1145</lpage><year>2008</year><pub-id pub-id-type="doi">10.1152/ajprenal.00396.2007</pub-id><pub-id pub-id-type="pmid">18322020</pub-id></element-citation></ref>
<ref id="b16-mmr-17-01-1289"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>1,25(OH)2D3 inhibits high glucose-induced apoptosis and ROS production in human peritoneal mesothelial cells via the MAPK/P38 pathway</article-title><source>Mol Med Rep</source><volume>14</volume><fpage>839</fpage><lpage>844</lpage><year>2016</year><pub-id pub-id-type="doi">10.3892/mmr.2016.5323</pub-id><pub-id pub-id-type="pmid">27220355</pub-id></element-citation></ref>
<ref id="b17-mmr-17-01-1289"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>M</given-names></name><name><surname>Pickrell</surname><given-names>AM</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bacman</surname><given-names>SR</given-names></name><name><surname>Yu</surname><given-names>A</given-names></name><name><surname>Hida</surname><given-names>A</given-names></name><name><surname>Dillon</surname><given-names>LM</given-names></name><name><surname>Morton</surname><given-names>PD</given-names></name><name><surname>Malek</surname><given-names>TR</given-names></name><name><surname>Williams</surname><given-names>SL</given-names></name><name><surname>Moraes</surname><given-names>CT</given-names></name></person-group><article-title>Transient mitochondrial DNA double strand breaks in mice cause accelerated aging phenotypes in a ROS-dependent but p53/p21-independent manner</article-title><source>Cell Death Differ</source><volume>24</volume><fpage>288</fpage><lpage>299</lpage><year>2017</year><pub-id pub-id-type="doi">10.1038/cdd.2016.123</pub-id><pub-id pub-id-type="pmid">27911443</pub-id></element-citation></ref>
<ref id="b18-mmr-17-01-1289"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>X</given-names></name><name><surname>Lederman</surname><given-names>R</given-names></name><name><surname>Eng</surname><given-names>JM</given-names></name><name><surname>Shoshtari</surname><given-names>SS</given-names></name><name><surname>Saleem</surname><given-names>MA</given-names></name><name><surname>Malhotra</surname><given-names>A</given-names></name><name><surname>Singhal</surname><given-names>PC</given-names></name></person-group><article-title>Nicotine induces podocyte apoptosis through increasing oxidative stress</article-title><source>PLoS One</source><volume>11</volume><fpage>e0167071</fpage><year>2016</year><pub-id pub-id-type="doi">10.1371/journal.pone.0167071</pub-id><pub-id pub-id-type="pmid">27907022</pub-id><pub-id pub-id-type="pmcid">5132002</pub-id></element-citation></ref>
<ref id="b19-mmr-17-01-1289"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>K</given-names></name><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name></person-group><article-title>NOX2-ROS-HIF-1a signaling is critical for the inhibitory effect of oleanolic acid on rectal cancer cell proliferation</article-title><source>Biomed Pharmacother</source><volume>85</volume><fpage>733</fpage><lpage>739</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.biopha.2016.11.091</pub-id><pub-id pub-id-type="pmid">27938946</pub-id></element-citation></ref>
<ref id="b20-mmr-17-01-1289"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhyu</surname><given-names>DY</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ha</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>GT</given-names></name><name><surname>Song</surname><given-names>JS</given-names></name><name><surname>Uh</surname><given-names>ST</given-names></name><name><surname>Lee</surname><given-names>HB</given-names></name></person-group><article-title>Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells</article-title><source>J Am Soc Nephrol</source><volume>16</volume><fpage>667</fpage><lpage>675</lpage><year>2005</year><pub-id pub-id-type="doi">10.1681/ASN.2004050425</pub-id><pub-id pub-id-type="pmid">15677311</pub-id></element-citation></ref>
<ref id="b21-mmr-17-01-1289"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>T</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group><article-title>Resveratrol prevents high glucose-induced epithelial-mesenchymal transition in renal tubular epithelial cells by inhibiting NADPH oxidase/ROS/ERK pathway</article-title><source>Mol Cell Endocrinol</source><volume>402</volume><fpage>13</fpage><lpage>20</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.mce.2014.12.010</pub-id><pub-id pub-id-type="pmid">25540919</pub-id></element-citation></ref>
<ref id="b22-mmr-17-01-1289"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>JC</given-names></name><name><surname>Thallas-Bonke</surname><given-names>V</given-names></name><name><surname>Banal</surname><given-names>C</given-names></name><name><surname>Gray</surname><given-names>SP</given-names></name><name><surname>Chow</surname><given-names>BS</given-names></name><name><surname>Ramm</surname><given-names>G</given-names></name><name><surname>Quaggin</surname><given-names>SE</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name><name><surname>Schmidt</surname><given-names>HH</given-names></name><name><surname>Jandeleit-Dahm</surname><given-names>KA</given-names></name></person-group><article-title>Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy</article-title><source>Diabetologia</source><volume>59</volume><fpage>379</fpage><lpage>389</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s00125-015-3796-0</pub-id><pub-id pub-id-type="pmid">26508318</pub-id></element-citation></ref>
<ref id="b23-mmr-17-01-1289"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>SB</given-names></name><name><surname>Liu</surname><given-names>GL</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Zhang</surname><given-names>JJ</given-names></name></person-group><article-title>Epithelial-to-mesenchymal transdifferentiation of renal tubular epithelial cell mediated by oxidative stress and intervention effect of probucol in diabetic nephropathy rats</article-title><source>Ren Fail</source><volume>34</volume><fpage>1244</fpage><lpage>1251</lpage><year>2012</year><pub-id pub-id-type="doi">10.3109/0886022X.2012.718711</pub-id><pub-id pub-id-type="pmid">23009159</pub-id></element-citation></ref>
<ref id="b24-mmr-17-01-1289"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>KL</given-names></name><name><surname>Wang</surname><given-names>CX</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>LL</given-names></name><name><surname>Ni</surname><given-names>HF</given-names></name><name><surname>Chen</surname><given-names>YX</given-names></name><name><surname>Ruan</surname><given-names>XZ</given-names></name><name><surname>Liu</surname><given-names>BC</given-names></name></person-group><article-title>Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cells</article-title><source>Lipids Health Dis</source><volume>12</volume><fpage>49</fpage><year>2013</year><pub-id pub-id-type="doi">10.1186/1476-511X-12-49</pub-id><pub-id pub-id-type="pmid">23570453</pub-id><pub-id pub-id-type="pmcid">3706287</pub-id></element-citation></ref>
<ref id="b25-mmr-17-01-1289"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eddy</surname><given-names>AA</given-names></name></person-group><article-title>Progression in chronic kidney disease</article-title><source>Adv Chronic Kidney Dis</source><volume>12</volume><fpage>353</fpage><lpage>365</lpage><year>2005</year><pub-id pub-id-type="doi">10.1053/j.ackd.2005.07.011</pub-id><pub-id pub-id-type="pmid">16198274</pub-id></element-citation></ref>
<ref id="b26-mmr-17-01-1289"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klahr</surname><given-names>S</given-names></name><name><surname>Morrissey</surname><given-names>J</given-names></name><name><surname>Hruska</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name></person-group><article-title>New approaches to delay the progression of chronic renal failure</article-title><source>Kidney Int Suppl</source><fpage>S23</fpage><lpage>S26</lpage><year>2002</year><pub-id pub-id-type="doi">10.1046/j.1523-1755.62.s82.5.x</pub-id><pub-id pub-id-type="pmid">12410850</pub-id></element-citation></ref>
<ref id="b27-mmr-17-01-1289"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Duan</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name></person-group><article-title>High glucose enhances oxLDL-induced apoptosis in human renal proximal tubular epithelial cells largely via inducing lectin-like ox-LDL receptor-1</article-title><source>Pharmacology</source><volume>98</volume><fpage>20</fpage><lpage>28</lpage><year>2016</year><pub-id pub-id-type="doi">10.1159/000444934</pub-id><pub-id pub-id-type="pmid">27003929</pub-id></element-citation></ref>
<ref id="b28-mmr-17-01-1289"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ruan</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>Role of LOX-1 in Ang II-induced oxidative functional damage in renal tubular epithelial cells</article-title><source>Int J Mol Med</source><volume>26</volume><fpage>679</fpage><lpage>690</lpage><year>2010</year><pub-id pub-id-type="doi">10.3892/ijmm_00000514</pub-id><pub-id pub-id-type="pmid">20878090</pub-id></element-citation></ref>
<ref id="b29-mmr-17-01-1289"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Palade</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Mercanti</surname><given-names>F</given-names></name><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Dai</surname><given-names>D</given-names></name><name><surname>Mehta</surname><given-names>JL</given-names></name></person-group><article-title>High fat diet causes renal fibrosis in LDLr-null mice through MAPK-NF-&#x03BA;B pathway mediated by Ox-LDL</article-title><source>J Cardiovasc Pharmacol</source><volume>63</volume><fpage>158</fpage><lpage>166</lpage><year>2014</year><pub-id pub-id-type="doi">10.1097/FJC.0000000000000035</pub-id><pub-id pub-id-type="pmid">24220312</pub-id></element-citation></ref>
<ref id="b30-mmr-17-01-1289"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CY</given-names></name><name><surname>Shen</surname><given-names>CY</given-names></name><name><surname>Kang</surname><given-names>CK</given-names></name><name><surname>Sher</surname><given-names>YP</given-names></name><name><surname>Sheu</surname><given-names>WH</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name></person-group><article-title>Taurine protects HK-2 cells from oxidized LDL-induced cytotoxicity via the ROS-mediated mitochondrial and p53-related apoptotic pathways</article-title><source>Toxicol Appl Pharmacol</source><volume>279</volume><fpage>351</fpage><lpage>363</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.taap.2014.06.029</pub-id><pub-id pub-id-type="pmid">25018059</pub-id></element-citation></ref>
<ref id="b31-mmr-17-01-1289"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tran</surname><given-names>Q</given-names></name><name><surname>Mun</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Hur</surname><given-names>GM</given-names></name><name><surname>Wen</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>J</given-names></name></person-group><article-title>Shen-Kang protects 5/6 nephrectomized rats against renal injury by reducing oxidative stress through the MAPK signaling pathways</article-title><source>Int J Mol Med</source><volume>36</volume><fpage>975</fpage><lpage>984</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/ijmm.2015.2328</pub-id><pub-id pub-id-type="pmid">26310779</pub-id><pub-id pub-id-type="pmcid">4564094</pub-id></element-citation></ref>
<ref id="b32-mmr-17-01-1289"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wankun</surname><given-names>X</given-names></name><name><surname>Wenzhen</surname><given-names>Y</given-names></name><name><surname>Min</surname><given-names>Z</given-names></name><name><surname>Weiyan</surname><given-names>Z</given-names></name><name><surname>Huan</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Lvzhen</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xiaoxin</surname><given-names>L</given-names></name></person-group><article-title>Protective effect of paeoniflorin against oxidative stress in human retinal pigment epithelium in vitro</article-title><source>Mol Vis</source><volume>17</volume><fpage>3512</fpage><lpage>3522</lpage><year>2011</year><pub-id pub-id-type="pmid">22219646</pub-id><pub-id pub-id-type="pmcid">3249435</pub-id></element-citation></ref>
<ref id="b33-mmr-17-01-1289"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>L</given-names></name></person-group><article-title>Antioxidant effect of imperatorin from Angelica dahurica in hypertension via inhibiting NADPH oxidase activation and MAPK pathway</article-title><source>J Am Soc Hypertens</source><volume>8</volume><fpage>527</fpage><lpage>536</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.jash.2014.04.006</pub-id><pub-id pub-id-type="pmid">24973900</pub-id></element-citation></ref>
<ref id="b34-mmr-17-01-1289"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>ZJ</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Piao</surname><given-names>YJ</given-names></name><name><surname>Choi</surname><given-names>DK</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Sohn</surname><given-names>KC</given-names></name><name><surname>Kim</surname><given-names>CD</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>Genkwadaphnin induces reactive oxygen species (ROS)-mediated apoptosis of squamous cell carcinoma (SCC) cells</article-title><source>Biochem Biophys Res Commun</source><volume>450</volume><fpage>1115</fpage><lpage>1119</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.06.118</pub-id><pub-id pub-id-type="pmid">24996181</pub-id></element-citation></ref>
<ref id="b35-mmr-17-01-1289"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Day</surname><given-names>ML</given-names></name><name><surname>Poronnik</surname><given-names>P</given-names></name><name><surname>Pollock</surname><given-names>CA</given-names></name><name><surname>Chen</surname><given-names>XM</given-names></name></person-group><article-title>Inhibition of KCa3.1 suppresses TGF-b1 induced MCP-1 expression in human proximal tubular cells through Smad3, p38 and ERK1/2 signaling pathways</article-title><source>Int J Biochem Cell Biol</source><volume>47</volume><fpage>1</fpage><lpage>10</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.biocel.2013.11.017</pub-id><pub-id pub-id-type="pmid">24291552</pub-id></element-citation></ref>
<ref id="b36-mmr-17-01-1289"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Chi</surname><given-names>ZH</given-names></name><name><surname>Chu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>RZ</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Effect of zinc on high glucose-induced epithelial-to-mesenchymal transition in renal tubular epithelial cells</article-title><source>Int J Mol Med</source><volume>35</volume><fpage>1747</fpage><lpage>1754</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/ijmm.2015.2170</pub-id><pub-id pub-id-type="pmid">25872526</pub-id></element-citation></ref>
<ref id="b37-mmr-17-01-1289"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>JP</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>HY</given-names></name></person-group><article-title>SiRNA-HMGA2 weakened AGEs-induced epithelial-to-mesenchymal transition in tubular epithelial cells</article-title><source>Biochem Biophys Res Commun</source><volume>457</volume><fpage>730</fpage><lpage>735</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.01.063</pub-id><pub-id pub-id-type="pmid">25623534</pub-id></element-citation></ref>
<ref id="b38-mmr-17-01-1289"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name></person-group><article-title>Angiotensin-(1&#x2013;7) attenuates high glucose-induced proximal tubular epithelial-to-mesenchymal transition via inhibiting ERK1/2 and p38 phosphorylation</article-title><source>Life Sci</source><volume>90</volume><fpage>454</fpage><lpage>462</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.lfs.2011.12.015</pub-id><pub-id pub-id-type="pmid">22285598</pub-id></element-citation></ref>
<ref id="b39-mmr-17-01-1289"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>SF</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Luo</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>XQ</given-names></name></person-group><article-title>Urinary proteins from patients with nephrotic syndrome alters the signalling proteins regulating epithelial-mesenchymal transition</article-title><source>Nephrology (Carlton)</source><volume>15</volume><fpage>63</fpage><lpage>74</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1440-1797.2009.01152.x</pub-id><pub-id pub-id-type="pmid">20377773</pub-id></element-citation></ref>
<ref id="b40-mmr-17-01-1289"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>H</given-names></name></person-group><article-title>Knockdown of thioredoxin-interacting protein ameliorates high glucose-induced epithelial to mesenchymal transition in renal tubular epithelial cells</article-title><source>Cell Signal</source><volume>25</volume><fpage>2788</fpage><lpage>2796</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.cellsig.2013.09.009</pub-id><pub-id pub-id-type="pmid">24041652</pub-id></element-citation></ref>
<ref id="b41-mmr-17-01-1289"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group><article-title>Probucol inhibited Nox2 expression and attenuated podocyte injury in type 2 diabetic nephropathy of db/db mice</article-title><source>Biol Pharm Bull</source><volume>36</volume><fpage>1883</fpage><lpage>1890</lpage><year>2013</year><pub-id pub-id-type="doi">10.1248/bpb.b12-00634</pub-id><pub-id pub-id-type="pmid">24432375</pub-id></element-citation></ref>
<ref id="b42-mmr-17-01-1289"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Masuda</surname><given-names>D</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Did we abandon probucol too soon?</article-title><source>Curr Opin Lipidol</source><volume>26</volume><fpage>304</fpage><lpage>316</lpage><year>2015</year><pub-id pub-id-type="doi">10.1097/MOL.0000000000000199</pub-id><pub-id pub-id-type="pmid">26125504</pub-id></element-citation></ref>
<ref id="b43-mmr-17-01-1289"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Hbujo</surname><given-names>H</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Harada-Shiba</surname><given-names>M</given-names></name><name><surname>Matsui</surname><given-names>S</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Long-term probucol treatment prevents secondary cardiovascular events: A cohort study of patients with heterozygous familial hypercholesterolemia in Japan</article-title><source>J Atheroscler Thromb</source><volume>15</volume><fpage>292</fpage><lpage>303</lpage><year>2008</year><pub-id pub-id-type="doi">10.5551/jat.E610</pub-id><pub-id pub-id-type="pmid">19060422</pub-id></element-citation></ref>
<ref id="b44-mmr-17-01-1289"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>Where are we with probucol: A new life for an old drug?</article-title><source>Atherosclerosis</source><volume>207</volume><fpage>16</fpage><lpage>23</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2009.04.002</pub-id><pub-id pub-id-type="pmid">19457483</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mmr-17-01-1289" position="float">
<label>Figure 1.</label>
<caption><p>Effect of Ox-LDL on the viability of HK-2 cells. HK-2 cells were induced with (A) 50 &#x00B5;g/ml Ox-LDL for different times (0, 12, 24, 36, 48 and 72 h) or (B) different dosages of Ox-LDL (0&#x2013;200 &#x00B5;g/ml) for 24 h, and then cell viability was measured by MTT assay. Four samples were used for each group, and the experiments were repeated four independent times. Data are presented as the means &#x00B1; standard deviation. Ox-LDL, oxidized low density lipoprotein.</p></caption>
<graphic xlink:href="MMR-17-01-1289-g00.tif"/>
</fig>
<fig id="f2-mmr-17-01-1289" position="float">
<label>Figure 2.</label>
<caption><p>Effect of Ox-LDL on the EMT status of HK-2 cells. Cells were stimulated with Ox-LDL (0&#x2013;100 &#x00B5;g/ml) for 24 h and the protein expression levels of LOX-1, E-cadherin and &#x03B1;-SMA were analyzed by western blotting. Representative images and quantification, with &#x03B2;-actin used as a loading control. &#x002A;P&#x003C;0.05 vs. control. Ox-LDL, oxidized low density lipoprotein; EMT, epithelial-mesenchymal transition; LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; SMA, smooth muscle actin.</p></caption>
<graphic xlink:href="MMR-17-01-1289-g01.tif"/>
</fig>
<fig id="f3-mmr-17-01-1289" position="float">
<label>Figure 3.</label>
<caption><p>Effect of probucol on Ox-LDL-induced EMT in HK-2 cells. Cells were pretreated with probucol or with the LOX-1 inhibitor polyinosinic acid, stimulated with Ox-LDL for 24 h, and then analyzed by western blotting. Representative images and quantification, with &#x03B2;-actin used as a loading control. &#x002A;P&#x003C;0.05 vs. control; <sup>#</sup>P&#x003C;0.05 vs. Ox-LDL alone; and <sup>&#x0026;</sup>P&#x003C;0.05 as indicated by bracket. Ox-LDL, oxidized low density lipoprotein; EMT, epithelial-mesenchymal transition; LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; SMA, smooth muscle actin; Con, control.</p></caption>
<graphic xlink:href="MMR-17-01-1289-g02.tif"/>
</fig>
<fig id="f4-mmr-17-01-1289" position="float">
<label>Figure 4.</label>
<caption><p>Effect of probucol on Ox-LDL-induced ROS generation and NOX4 and p22phox expression in HK-2 cells. Cells were pretreated with probucol or with the LOX-1 inhibitor polyinosinic acid, and then stimulated with Ox-LDL. (A) ROS production was measured with a specific probe and flow cytometry. (B) NO concentration was measured with a biochemical colorimetric method. (C) Protein expression levels of NOX4 and p22phox were examined by western blot analysis. Representative images and quantification, with &#x03B2;-actin used as a loading control. &#x002A;P&#x003C;0.05 vs. control; and <sup>#</sup>P&#x003C;0.05 vs. Ox-LDL alone. Ox-LDL, oxidized low density lipoprotein; ROS, reactive oxygen species; NOX4, NADPH oxidase 4; p22phox, cytochrome b-245 &#x03B1; chain; LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; NO, nitric oxide; Con, control.</p></caption>
<graphic xlink:href="MMR-17-01-1289-g03.tif"/>
</fig>
<fig id="f5-mmr-17-01-1289" position="float">
<label>Figure 5.</label>
<caption><p>Effect of probucol on ERK and p38 MAPK signaling in Ox-LDL-induced HK-2 cells. (A) Cells were stimulated with Ox-LDL (50 &#x00B5;g/ml) for 5, 15 and 30 min and then analyzed by western blotting, in order to determine the effect of Ox-LDL on ERK and p38 MAPK pathway activation. (B) Cells were pretreated with probucol (20 &#x00B5;mol/l) or with the LOX-1 inhibitor polyinosinic acid (250 &#x00B5;g/ml) for 2 h, stimulated with Ox-LDL (50 &#x00B5;g/ml) for 30 min, and then analyzed by western blotting. Representative images and quantification, with &#x03B2;-actin used as a loading control. &#x002A;P&#x003C;0.05 vs. control; and <sup>#</sup>P&#x003C;0.05 vs. Ox-LDL alone. ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; Ox-LDL, oxidized low density lipoprotein; LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; p, phosphorylated; Con, control.</p></caption>
<graphic xlink:href="MMR-17-01-1289-g04.tif"/>
</fig>
</floats-group>
</article>